Global RNAi Therapeutics Market Report 2023: Sector to Reach $1.26 Billion in 2027 at a CAGR of 10.02% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

The global RNAi therapeutics market is expected to record a value of US$1.26 billion in 2027, progressing at a CAGR of 10.02%, over the period 2023-2027.

Companies Mentioned

• Sanofi S.A(Genzyme Corporation)
• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Benitec Biopharma Ltd.
• Sirnaomics, Ltd.

Factors such as rising utilization in oncology pharmaceuticals, accelerating growth rates of infectious diseases, enlarging geriatric population, increasing prevalence of neurodegenerative disorders and progress in collaborations and associated deals in RNAi therapeutics.

However, the market growth would be challenged by complexity associated with the drug delivery of RNAi therapeutics, high development cost of RNA interference-based therapeutics and stringent regulatory requirements. A few notable trends include growing popularity of personalized medicine, surging preference RNAi therapeutics as an alternative for HTS & keloids treatment and escalating applications in molecular diagnostics.

The global market has been segmented on the basis of molecule type, application and end-user. On the basis of molecule type, the global market can be bifurcated into small interfering RNAs (siRNAs) and microRNAs (miRNAs).

According to applications, the market can be divided into oncology, respiratory disorders, neurological disorders, liver disorders, autoimmune disorders and other disorders. Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.

The fastest growing regional market is North America owing to increasing prevalence of chronic conditions, rising investments for development of RNAi therapeutics along with growing number of research activities for RNA-based therapeutics in the region. Further, the COVID-19 pandemic has positively impacted the market due to the growing relevance of RNA-based investigations as well as increasing funding for R&D activities.

Scope of the report

• The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.
• The major regional and country markets (North America, Europe, Asia Pacific and RoW) have been analyzed.
• The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players (Sanofi S.A., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Benitec Biopharma Ltd., and Sirnaomics, Ltd.) are also presented in detail.

Key Topics Covered:

1. Market Overview

2. Impact of COVID-19

2.1 Rapid Spread of Coronavirus

2.2 Growth in COVID-19 R&D Funding

2.3 RNA Vaccine Development for COVID-19

3. Global Market Analysis

3.1 Global RNAi Therapeutics Market by Value

3.2 Global RNAi Therapeutics Market Forecast by Value

3.3 Global RNAi Therapeutics Market by Molecule Type

3.3.1 Global Small Interfering RNA (siRNA) Therapeutics Market by Value

3.3.2 Global Small Interfering RNA (siRNA) Therapeutics Market Forecast by Value

3.3.3 Global Small Interfering RNA (siRNA) Therapeutics Market by Type

3.3.4 Global Small Interfering RNA (siRNA) Therapeutics Type Market by Value

3.3.5 Global Small Interfering RNA (siRNA) Therapeutics Type Market Forecast by Value

3.3.6 Global MicroRNA (miRNA) Therapeutics Market by Value

3.3.7 Global MicroRNA (miRNA) Therapeutics Market Forecast by Value

3.4 Global RNAi Therapeutics Market by Application

3.4.1 Global RNAi Therapeutics Application Market by Value

3.4.2 Global RNAi Therapeutics Product Market Forecast by Value

3.5 Global RNAi Therapeutics Market by End-Users

3.5.1 Global RNAi Therapeutics End-User Market by Value

3.5.2 Global RNAi Therapeutics End-User Market Forecast by Value

3.6 Global RNAi Therapeutics Market by Region

4. Regional Market Analysis

5. Market Dynamics

5.1 Growth Drivers

5.1.1 Rising Utilization in Oncology Pharmaceuticals

5.1.2 Accelerating Growth Rates of Infectious Diseases

5.1.3 Enlarging Geriatric Population

5.1.4 Increasing Prevalence of Neurodegenerative Disorders

5.1.5 Progress in Collaborations & Associated Deals in RNAi Therapeutics

5.1.6 Expanding Research & Development Activities

5.2 Key Trends and Developments

5.2.1 Growing Popularity of Personalized Medicine

5.2.2 Surging Preference as an Alternative for HTS & Keloids Treatment

5.2.3 Escalating Applications in Molecular Diagnostics

5.2.4 Development of RNAi Therapeutics

5.3 Challenges

5.3.1 Complexity Associated with the Delivery of RNAi Therapeutics

5.3.2 High Development Cost of RNA Interference-Based Therapeutics

5.3.3 Stringent Regulatory Requirements

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/lpuf9a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.